Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of KC1086 plus fulvestrant in HR-positive, HER2-negative advanced or metastatic breast cancer
CTR20263888Phase 2Active
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Oct 2026
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KC1086, fulvestrant in breast cancer, sponsored by Beijing Konruns Pharmaceutical Co., Ltd.. Started Oct 2026; status: active.
02
Drugs
KC1086fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20263888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263888.